Amkor Stock Surges 17% After $1.5 Billion Nvidia AI Packaging Partnership 
SpaceX Stock Slump Wipes Out Nearly $700 Billion From Elon Musk’s Paper Wealth 
Coca-Cola Raises Diet Coke Prices in India as Iran Conflict Disrupts Can Supply 
Oracle Stock Rises After Winning Up to $6.99 Billion U.S. Defense Software Contract 
Tech Stock Positioning Nears Neutral as Investor Rotation Enters Final Phase, Deutsche Bank Says 
CATL Shares Jump as $5.6 Billion Buyback Signals Confidence in Long-Term Growth 
Volkswagen Cuts 2026 Revenue Outlook as China Weakness, Trade Risks Weigh 
Brown-Forman Rejects Sazerac’s $15 Billion Takeover Bid as Family Backs Independence 
Shein Reports $99 Million Loss Ahead of Hong Kong IPO as U.S. Tariffs Hit Sales 
Intel, AMD Seek Long-Term China Server CPU Deals as AI Demand Drives Supply Crunch 
Galp Shares Fall After Q2 EBITDA Miss Despite Profit Beat and Higher Dividend 
Uber Stock Falls as Waymo Plans to End Robotaxi Partnership by 2028 
Nvidia Eyes $250B Guarantee for OpenAI’s Massive Ohio AI Data Center Project 
Paramount-Warner Bros. Merger Delayed Until 2027 Amid Antitrust Lawsuit 
Domino’s Weighs Appeal After Australian Court Rules Workers Were Misled on Pay 
Rubio Rejects AI ‘Kill Switch’ Claims as U.S. Defends American Technology Abroad 
AMD Unveils Helios AI Servers to Challenge Nvidia as OpenAI Adopts New Platform 
NEW YORK, Oct. 31, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Spectrum Pharmaceuticals, Inc. (“Spectrum Pharmaceuticals”) (NASDAQ:SPPI) between December 16, 2015 and September 16, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Nevada. If you purchased or otherwise acquired Spectrum Pharmaceuticals between December 16, 2015 and September 16, 2016, your rights may be affected by this action. To get more information go to:
http://www.zlk.com/pslra/spectrum-pharmaceuticals-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The Complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Food and Drug Administration (the "FDA") questioned whether the data from the 611 and 612 Studies were clinically significant; (2) the FDA informed defendants in December 2012 not to submit the New Drug Application based on data from the 611 and 612 Studies; and (3) accordingly, defendants' public statements concerning the Company's business, operations and prospects were materially false and misleading at all relevant times.
If you suffered a loss in Spectrum Pharmaceuticals you have until November 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
